Jakarta Molnuvirapir, the COVID-19 antiviral drug manufactured by the US pharmaceutical company, Merck, is priced below Rp1 million, Health Minister Budi Gunadi Sadikin stated.

“Our calculations are between US$40 and US$50 (around Rp570 thousand to Rp713 thousand), so it is not too expensive,” Minister Sadikin stated at the House of Representatives’ Commission IX hearing here on Monday.

The minister remarked that Molnupiravir can be consumed by COVID-19-positive patients, with oxygen saturation levels above 95, or those who experience mild symptoms.

Sadikin stated that COVID-19 patients, whose oxygen saturation levels are above 94 or 95, can be given the drug.

“Based on the clinical trials abroad, the cure rate of the drugs for patients is 50 percent. Hence, there is no need to go to the hospital,” he remarked.

Source: Antara News